Gout - breaking research and drug development
Our most Aug issue of UpdatesPlus - Gout is now available. To receive further information or instruction on how to access the service including our Dec 2013 backgrounder please contact fiona.watts@leaddiscovery.co.uk
Gout is a highly prevalent condition - recent US figures suggest that gout prevalence has grown 7-fold in the past 50yr to 8.1mn in 2009. The disease is caused by elevated serum uric acid, usually due to its reduced excretion and presents as recurrent inflammatory arthritis with joint destruction, pain and reduced mobility. Symptoms are especially severe in patients with tophi (nodular collections of monosodium urate crystals). Kidney stones are also evident. Gout is, like many chronic inflammatory conditions associated with serious co-morbidities including cardiovascular disease
Given the seriousness of gout we are always surprised with the limited therapeutic options and also the size of the drug development pipeline, especially given the commercial opportunities for developing companies
For the above reasons we produced a report at the end of 2013 to present the gout drug development landscape to help companies and physicians understand the gout treat and development landscape. This has now turned into a monthly report within our Updates plus portfolio
This month we analyze:
This alert comes from our UpdatesPlus - Gout service, a regular analysis providing depth information on all key recent events in the area. To receive further information or instruction on how to access the service including our Dec 2013 backgrounder please contact fiona.watts@leaddiscovery.co.uk
Gout is a highly prevalent condition - recent US figures suggest that gout prevalence has grown 7-fold in the past 50yr to 8.1mn in 2009. The disease is caused by elevated serum uric acid, usually due to its reduced excretion and presents as recurrent inflammatory arthritis with joint destruction, pain and reduced mobility. Symptoms are especially severe in patients with tophi (nodular collections of monosodium urate crystals). Kidney stones are also evident. Gout is, like many chronic inflammatory conditions associated with serious co-morbidities including cardiovascular disease
Given the seriousness of gout we are always surprised with the limited therapeutic options and also the size of the drug development pipeline, especially given the commercial opportunities for developing companies
For the above reasons we produced a report at the end of 2013 to present the gout drug development landscape to help companies and physicians understand the gout treat and development landscape. This has now turned into a monthly report within our Updates plus portfolio
This month we analyze:
- Updated EULAR recommendations on gout treatment which were presented at EULAR 2014
- A new patient reported outcomes tool evaluating the impact of tophi on QoL
- Takeda's new Phase 2 study of extended release febuxostat as the company prepares for generic incursion towards the end of the decade
- A Menarini sponsored Phase 4 safety study of febuxostat cardiovascular safety
- Long term data Ilaris data
- AstraZeneca's development of Lesinurad
- Pfizer's new pipeline candidate, PF-06743649
- Selecta's in-licensing of pegsiticase from 3SBio and the company's development plans
This alert comes from our UpdatesPlus - Gout service, a regular analysis providing depth information on all key recent events in the area. To receive further information or instruction on how to access the service including our Dec 2013 backgrounder please contact fiona.watts@leaddiscovery.co.uk
posted by Jon Goldhill at 8:49 AM
0 Comments:
Post a Comment
<< Home